Ultomiris FDA Approval Gives Soliris Biosimilars Bigger Hurdle

New Rapid Infusion Formulation Bolsters Originator

 
• By Dean Rudge
  
Barrier
Alexion has prospered in attempts to boost its C5 Inhibitor portfolio • Source: Shutterstock

More from Biosimilars

More from Products